The Alzheimer’s research landscape is undergoing a fundamental transformation. With disease-modifying therapies now a reality, sponsors must rethink how they design, recruit for, and execute trials—particularly in early-stage and preclinical populations. This guide explores five strategic imperatives that can help...
Expertise: Neuroscience 47 results
For decades, the Alzheimer’s disease (AD) treatment landscape remained largely static, focused on symptom management rather than disease modification. But in recent years, the field has entered a transformational period. With the emergence of new biomarkers, approval of novel anti-amyloid...
Neuroscience
Patient Empowerment World Congress Europe
Neuroscience
CNS Summit
Neuroscience
SCRS Global Site Solutions Summit
Neuroscience
Dr. Martin Strassnig
Neuroscience
Melissa Snyder, Ph.D.
Neuroscience
Gladys Valdez, Ph.D.
In central nervous system (CNS) clinical trials, the integrity of clinician- and patient-reported outcomes is essential to generating reliable, high-quality data. Given the complexity of neurological disorders and the subjective nature of key endpoints, even small inconsistencies in assessment administration...